Skip to main content

Fiscal Wizard · Single-issue tearsheet

BCDA / Jun 21, 2026 Run #7425

BCDA

BioCardia, Inc.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Composite verdict

F 9.5 / 100
Bearish setup · Trend Following 11 drivers · 5 gates blocking
  • Trendline Break
  • Vortex Signal
  • Donchian Breakout
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 446th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 18 signals100% Bear
Momentum Bearish 6Mean-reversion Neutral 47

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

19.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Return on Capital Employed 0
Days Sales Outstanding 100
Return on Assets 0
EPS Growth (YoY) 100
Greenblatt ROC 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Trendline Break, Vortex Signal, Donchian Breakout); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Trendline Break 12
Vortex Signal 15
Donchian Breakout 15

Risk Gates

5 blocking 3 caution

5 guards active, 23 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BCDA.